{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224124","form_type":"8-K","ticker":"TRAX","cik":"0002091349","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-05-14T20:24:52+00:00","discovered_at":"2026-05-14T20:26:00.183526+00:00","generated_at":"2026-05-14T20:27:05.280712+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"First Tracks Q1 net loss $50.5M; launched with $180M cash; ANB033 Phase 1b data expected Q4 2026","bullets":["Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025; R&D expense $34.0M (down from $41.5M).","Launched on April 20 with $180M cash and a two-year runway to fund ANB033 and other programs.","ANB033 Phase 1b trials in celiac disease and eosinophilic esophagitis ongoing; top-line data Q4 2026 and mid-2027.","Rosnilimab had productive End-of-Phase 2 FDA meeting for RA; company assessing strategic options.","G&A expense rose to $18.9M from $9.8M due to separation costs and stock compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224124","json":"https://secwatch.observer/filing/0001193125-26-224124.json","markdown":"https://secwatch.observer/filing/0001193125-26-224124.md","text":"https://secwatch.observer/filing/0001193125-26-224124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/0001193125-26-224124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:27:05.280712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a70f2374a4ec88513960da58d867bc5fd2abb1a5","claim":"First Tracks Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $50.5 million for the three months ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, First Tracks Biotherapeutics, Inc. (“First Tracks”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/0001193125-26-224124-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $50.5 million for the three months ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}